

Sub study information

There are 21 ASCOT sub-studies currently being carried out in the UK, Ireland and Nordic regions:

All sub-study protocols are published in the Journal of Human Hypertension.

(*J. Hum. Hypertens.* (2001) 15, suppl 1).

1. **An intensive phenotyping study to enable the future examination of genetic influences on hypertension-associated cardiovascular disease**

Alice Stanton, Royal College of Surgeons, Ireland

2. **Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure**

Paavo Uusimaa, University of Oulu, Finland

3. **Cardiovascular risk factors in a cohort of 30 000 high-risk men and women in the UK: cross-sectional, retrospective and prospective studies of screenees for the Anglo-Scandinavian Cardiac Outcomes Trial**

Naomi Glaser, Cardiovascular Studies Unit, London, UK

4. **Effects of atorvastatin (and blood pressure lowering comparing amlodipine-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo**

Markku Nieminen, Helsinki University Hospital, Finland

5. Evaluation of cardiovascular risk equations using the ASCOT cohort

Sarah Wilson, St Bartholomew's and the Royal London School of Medicine and Dentistry, UK

6. Health-related quality of life and psychological factors in treatment of hypertension

Juhani Julkunen, University of Helsinki, Finland

7. Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of hypertensive treatment

G Y H Lip, City Hospital, Birmingham, UK

8. Comparative effects of atenolol-based and amlodipine-based hypertensive therapy on QT dispersion in hypertensive subjects

Lasse Oikarinen, Helsinki University General Hospital, Finland

9. Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients

Eoin O'Brien, Beaumont Hospital, Dublin, Ireland

10. Health economics of prevention of coronary heart disease and vascular events: a cost-effectiveness analysis based on the Anglo-Scandinavian Cardiac Outcomes Trial

Bengt Jönsson, Stockholm School of Economics, Sweden

11. Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease

DJ Collier, St Bartholomew's and the Royal London School of Medicine and Dentistry, UK

12. Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group

Naomi Glaser, Cardiovascular Studies Unit, London, UK

13. Do hypertensive patients' beliefs about their illness and treatment influence medication adherence and quality of life?

Robert Horne, Centre for Health Care Research, Brighton, UK

14. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT

Bryan Williams, University of Leicester, UK

15. Left ventricular hypertrophy and silent ischaemia: a pilot study to examine the relationship in hypertensive patients

Eoin O'Brien, Beaumont Hospital, Dublin, Ireland

16. Microalbuminuria in type 2 diabetic hypertensive patients in ASCOT

J P O'Hare, Hospital of St Cross, Rugby, UK

17. Non-specific effects of inclusion in a clinical trial: information from ASCOT

Simon Thom, St Mary's Hospital, London, UK

18. The suitability of an automated blood pressure measuring device - the Omron HEM-705CP - in a large multicentre study: the ASCOT study

Eoin O'Brien, Beaumont Hospital, Dublin, Ireland

19. Ethnic variations in response to a statin (EVIREST)

Neil Poulter, Imperial College School of Medicine, London, UK

20. The effects of cardiac events on quality of life and indirect costs

Neil Poulter, Imperial College School of Medicine, London, UK

21. Microvolt T wave alternans in patients with hypertension and left ventricular hypertrophy

Nicholas Peters, St Mary's Hospital, London, UK